AVBCC honors Iovance CEO Fred Vogt with inaugural cancer innovation award

The Association for Value-Based Cancer Care gave its first Global Cancer Research & Innovation Award to Iovance Biotherapeutics leader Fred Vogt at its annual symposium in New York. The honor highlights Vogt’s role in advancing Amtagvi, the first FDA-approved cell therapy for a solid tumor, and Iovance’s push to expand TIL therapy.

Why it matters: - The award spotlights leaders shaping the next phase of cancer treatment, especially cell therapy for solid tumors. - Vogt’s recognition ties directly to the commercialization of Amtagvi, which opened a new treatment category for advanced melanoma. - The honor also reflects broader attention on companies building the manufacturing and clinical infrastructure needed to bring complex therapies to more patients.

What happened: - The Association for Value-Based Cancer Care named Fred Vogt, PhD, JD, interim CEO, president and general counsel of Iovance Biotherapeutics, as the first recipient of its Global Cancer Research & Innovation Award. - AVBCC presented the award on Oct. 6, 2026, at its 2nd Annual Global Cancer Research & Innovation Symposium in New York. - AVBCC created the award to recognize leadership and contributions to oncology innovation.

The details: - AVBCC said the symposium serves as a forum for experts to discuss breakthrough science, emerging therapies and innovations changing cancer care worldwide. - Burt Zweigenhaft, AVBCC’s executive director and founder, said Vogt’s scientific leadership, strategic vision and commitment to breakthrough therapies matched the intent of the new award. - Vogt said the recognition reflects the work of the Iovance team to make TIL therapy a reality for patients with advanced melanoma. - Vogt pointed to the approval and launch of Amtagvi as evidence that cell therapy can change the treatment landscape for solid tumors. - In 2024, Vogt led Iovance through FDA approval and commercial launch of Amtagvi, also known as lifileucel. - Iovance said Amtagvi is the first cell therapy ever approved for a solid tumor. - Vogt also oversaw the development of Iovance’s end-to-end manufacturing infrastructure and commercial transition. - Iovance acquired and integrated Proleukin, which the company said strengthened support for the TIL therapy regimen. - Vogt has more than 25 years of experience advancing cancer therapies and helped contribute to the approvals of Hycamtin, Votrient, Tafinlar, Mekinist and Arzerra.

Between the lines: - AVBCC is using the inaugural award to elevate executives who can bridge science, business and patient access. - The recognition also underscores how much of the value in cell therapy now depends on manufacturing scale, commercialization execution and reimbursement readiness, not just clinical science. - Vogt’s dual background as a scientist and business leader fits a moment when oncology innovation increasingly depends on both disciplines.

What's next: - Iovance said its TIL platform continues through registrational trials and next-generation programs in other solid tumors. - The company is developing gene-edited and IL-12 tethered TIL therapies, next-generation IL-2 and precision immuno-oncology approaches. - Iovance said Amtagvi is approved in three global markets and available at nearly 100 authorized treatment centers. - The company said its U.S.-based manufacturing is scaled to serve thousands of cancer patients worldwide each year. - AVBCC will likely continue using GCRIS as a platform to highlight emerging cancer research and innovation.

The bottom line: - AVBCC’s first cancer innovation award goes to a leader whose biggest mark is helping turn TIL therapy from an idea into a commercial reality.